| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8387612 | NOVA PNEUMA | Self-contained heating unit and drug-supply unit employing same |
Oct, 2026
(28 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Dec 21, 2015 |
Drugs and Companies using LOXAPINE ingredient
Market Authorisation Date: 21 December, 2012
Treatment: NA
Dosage: POWDER
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ABBVIE | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-738) | Jun 22, 2019 |
| New Chemical Entity Exclusivity(NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 25, 2025 |
| New Patient Population(NPP) | Jan 26, 2027 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: 25 February, 2019
Market Authorisation Date: 25 February, 2015
Treatment: NA
Dosage: POWDER
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7598276 | PORTOLA | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(12 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9555023 | PORTOLA | Pharmaceutical salts and polymorphs of a factor Xa inhibitor |
Nov, 2026
(13 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 23, 2022 |
Drugs and Companies using BETRIXABAN ingredient
NCE-1 date: 23 June, 2021
Market Authorisation Date: 23 June, 2017
Treatment: Prophylaxis of pulmonary embolism
Dosage: CAPSULE
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ABBVIE | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(8 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 07, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Feb 07, 2033 |
Drugs and Companies using AVIBACTAM SODIUM; AZTREONAM ingredient
Market Authorisation Date: 07 February, 2025
Treatment: NA
Dosage: POWDER
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9388134 | NOVARTIS | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(12 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2020 |
| New Patient Population(NPP) | Oct 01, 2022 |
| Pediatric Exclusivity(PED) | Apr 01, 2023 |
| M(M-82) | Feb 16, 2024 |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
NCE-1 date: 01 April, 2022
Market Authorisation Date: 07 July, 2015
Treatment: Treatment of heart failure
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9388134 | NOVARTIS | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(12 days ago) | |
Drugs and Companies using SACUBITRIL; VALSARTAN ingredient
Market Authorisation Date: 12 April, 2024
Treatment: Treatment of heart failure
Dosage: CAPSULE, PELLETS
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8975243 | TAKEDA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| US8497258 | TAKEDA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| US8679545 | TAKEDA | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| US11413296 | TAKEDA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| US11197822 | TAKEDA | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| US9119863 | TAKEDA | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
Nov, 2026
(11 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 09, 2027 |
| Orphan Drug Exclusivity(ODE-466) | Feb 09, 2031 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 09 February, 2024
Treatment: Treatment of eosinophilic esophagitis
Dosage: SUSPENSION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8981103 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| US7635704 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 25, 2020 |
| New Chemical Entity Exclusivity(NCE) | Nov 05, 2020 |
| New Dosing Schedule(D-173) | Dec 10, 2021 |
NCE-1 date: 06 November, 2019
Market Authorisation Date: 05 November, 2015
Treatment: Treatment of hiv infection
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9539258 | BOEHRINGER INGELHEIM | Quinazoline derivatives for the treatment of cancer diseases |
Nov, 2026
(11 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 12, 2018 |
| New Indication(I-730) | Apr 15, 2019 |
| Orphan Drug Exclusivity(ODE-50) | Jul 12, 2020 |
| New Indication(I-763) | Jan 12, 2021 |
| Orphan Drug Exclusivity(ODE) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-115) | Apr 15, 2023 |
| Orphan Drug Exclusivity(ODE-230) | Jan 12, 2025 |
| M(M-276) | Apr 07, 2025 |
| Pediatric Exclusivity(PED) | Oct 07, 2025 |
Drugs and Companies using AFATINIB DIMALEATE ingredient
NCE-1 date: 07 October, 2024
Market Authorisation Date: 12 July, 2013
Treatment: Treatment of patients with advanced (metastatic) non-small cell lung cancer whose disease progressed during or after platinum-based chemotherapy
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12171739 | BOEHRINGER INGELHEIM | N4-Phenyl-Quinazoline-4-Amine Derivatives And Related Compounds As Erbb Type I Receptor Tyrosine Kinase Inhibitors For The Treatment Of Hyperproliferative Diseases |
Nov, 2026
(5 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 08, 2030 |
Drugs and Companies using ZONGERTINIB ingredient
NCE-1 date: 08 August, 2029
Market Authorisation Date: 08 August, 2025
Treatment: NA
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8026279 | AZURITY | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(10 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-652) | Jun 06, 2015 |
| New Chemical Entity Exclusivity(NCE) | Apr 06, 2016 |
| Orphan Drug Exclusivity(ODE) | Jun 06, 2019 |
| Orphan Drug Exclusivity(ODE-25) | Jun 06, 2019 |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
NCE-1 date: 07 April, 2015
Market Authorisation Date: 13 December, 2011
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(18 days ago) | |
| US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(18 days ago) | |
| US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(18 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 11, 2020 |
| Pediatric Exclusivity(PED) | Apr 11, 2021 |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9216969 | VERTEX | Modulators of ATP-binding cassette transporters |
Nov, 2026
(12 days ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9216969 | VERTEX | Modulators of ATP-binding cassette transporters |
Nov, 2026
(12 days ago) | |
| US8741933 | VERTEX | Modulators of ATP-binding cassette transporters |
Nov, 2026
(12 days ago) | |
| US7973038 | VERTEX | Modulators of ATP-binding cassette transporters |
Nov, 2026
(12 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Sep 02, 2025 |
| Pediatric Exclusivity(PED) | Jun 13, 2028 |
| New Chemical Entity Exclusivity(NCE) | Jul 02, 2020 |
| M(M-218) | Jan 25, 2021 |
| New Product(NP) | Aug 07, 2021 |
| Orphan Drug Exclusivity(ODE-93) | Jul 02, 2022 |
| Orphan Drug Exclusivity(ODE) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-123) | Sep 28, 2023 |
| Orphan Drug Exclusivity(ODE-195) | Aug 07, 2025 |
| New Strength(NS) | Sep 02, 2025 |
| Generating Antibiotic Incentives Now(GAIN) | Jan 02, 2028 |
| M(M-14) | Dec 13, 2027 |
| Orphan Drug Exclusivity(ODE-408) | Sep 02, 2029 |
Drugs and Companies using IVACAFTOR; LUMACAFTOR ingredient
NCE-1 date: 03 July, 2019
Market Authorisation Date: 02 September, 2022
Treatment: Treatment of cystic fibrosis in a patient age 1-5 years who is homozygous for the f508del mutation in the cftr gene using lumacaftor and ivacaftor; Treatment of cystic fibrosis in a patient age 2-5 ye...
Dosage: GRANULE; TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11110093 | INDIVIOR | Sustained release small molecule drug formulation |
Nov, 2026
(15 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 27, 2021 |
Drugs and Companies using RISPERIDONE ingredient
Market Authorisation Date: 27 July, 2018
Treatment: Treating schizophrenia
Dosage: FOR SUSPENSION, EXTENDED RELEASE
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 14, 2017 |
| New Product(NP) | Dec 15, 2017 |
| New Indication(I-785) | Jun 29, 2021 |
| Orphan Drug Exclusivity(ODE) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-81) | Dec 15, 2021 |
| Orphan Drug Exclusivity(ODE-268) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
NCE-1 date: 14 December, 2016
Market Authorisation Date: 29 June, 2018
Treatment: NA
Dosage: FOR SUSPENSION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7635704 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| US8981103 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 27, 2015 |
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Indication(I-704) | Dec 17, 2017 |
| New Patient Population(NPP) | Jan 27, 2020 |
NCE-1 date: 27 August, 2016
Market Authorisation Date: 27 August, 2012
Treatment: Treatment of hiv infection
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9056076 | APELLIS | Method of treating age-related macular degeneration comprising administering a compstatin analog |
Oct, 2026
(26 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Feb 22, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 14, 2026 |
Drugs and Companies using PEGCETACOPLAN ingredient
NCE-1 date: 14 May, 2025
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of geographic atrophy secondary to age-related macular degeneration by intravitreal administration of pegcetacoplan
Dosage: SOLUTION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6987103 | TEVA | Treatment of chronic myelogenous leukmia, resistant or intolerant to ST1571, involving homoharringtonine alone or combined with other agents |
Oct, 2026
(25 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 26, 2017 |
| Orphan Drug Exclusivity(ODE) | Oct 26, 2019 |
| Orphan Drug Exclusivity(ODE-32) | Oct 26, 2019 |
Drugs and Companies using OMACETAXINE MEPESUCCINATE ingredient
NCE-1 date: 26 October, 2016
Market Authorisation Date: 26 October, 2012
Treatment: Treatment of patients with tyrosine kinase inhibitor (tki) resistant or intolerant chronic myeloid/myelogenous leukemia (cml)
Dosage: POWDER
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7452895 | SEAGEN | Quinazoline analogs as receptor tyrosine kinase inhibitors |
Nov, 2026
(4 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 17, 2025 |
| New Indication(I-906) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-309) | Apr 17, 2027 |
| New Indication(I-1003) | Oct 07, 2029 |
| Orphan Drug Exclusivity(ODE-422) | Jan 19, 2030 |
Drugs and Companies using TUCATINIB ingredient
NCE-1 date: 17 April, 2024
Market Authorisation Date: 17 April, 2020
Treatment: Treatment of breast cancer including her2 (erbb2)-positive or -overexpressing breast cancer
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7205302 | ACTELION | Heterocyclic compound derivatives and medicines |
Oct, 2026
(20 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 21, 2020 |
| Orphan Drug Exclusivity(ODE) | Dec 21, 2022 |
| Orphan Drug Exclusivity(ODE-106) | Dec 21, 2022 |
| New Patient Population(NPP) | May 23, 2029 |
| New Strength(NS) | May 23, 2029 |
| Pediatric Exclusivity(PED) | Nov 23, 2029 |
Drugs and Companies using SELEXIPAG ingredient
Market Authorisation Date: 29 July, 2021
Treatment: Method of treating pulmonary arterial hypertension comprising administering a pharmaceutical composition comprising selexipag
Dosage: POWDER; TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8981103 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| US7635704 | GILEAD | Stable crystal of 4-oxoquinoline compound |
Oct, 2026
(25 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 27, 2017 |
| New Product(NP) | Sep 24, 2017 |
Drugs and Companies using ELVITEGRAVIR ingredient
NCE-1 date: 27 August, 2016
Market Authorisation Date: 24 September, 2014
Treatment: Treatment of hiv infection
Dosage: TABLET
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7812163 | LNHC | Methods and compositions for controlling ectoparasites |
Oct, 2026
(23 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 24, 2025 |
Drugs and Companies using ABAMETAPIR ingredient
NCE-1 date: 24 July, 2024
Market Authorisation Date: 24 July, 2020
Treatment: Topical treatment of head lice infestation in patients 6 months of age and older
Dosage: LOTION
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7504509 | HOFFMANN LA ROCHE | Compounds and methods for development of Ret modulators |
Oct, 2026
(29 days ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 17, 2016 |
| Orphan Drug Exclusivity(ODE) | Aug 17, 2018 |
| Orphan Drug Exclusivity(ODE-13) | Aug 17, 2018 |
| M(M-184) | Aug 31, 2019 |
| New Indication(I-757) | Nov 06, 2020 |
| Orphan Drug Exclusivity(ODE-158) | Nov 06, 2024 |
Drugs and Companies using VEMURAFENIB ingredient
NCE-1 date: 18 August, 2015
Market Authorisation Date: 17 August, 2011
Treatment: NA
Dosage: TABLET